```
=> d his ful

     (FILE 'HOME' ENTERED AT 16:20:29 ON 03 AUG 2005)

     FILE 'REGISTRY' ENTERED AT 16:20:37 ON 03 AUG 2005

L5             STR L3
L6          21 SEA SSS SAM L5
L7        6463 SEA SSS FUL L5
L12            STR
L13         84 SEA SUB=L7 SSS FUL L12
L15            STR
L16         42 SEA SUB=L7 SSS FUL L15

     FILE 'HCAPLUS' ENTERED AT 16:40:04 ON 03 AUG 2005
L17          7 SEA ABB=ON  PLU=ON  L16
               D STAT QUE L17
               D IBIB ABS HITSTR L17 1-7

     FILE 'REGISTRY' ENTERED AT 16:41:35 ON 03 AUG 2005
L18         42 SEA ABB=ON  PLU=ON  L13 NOT L16

     FILE 'HCAPLUS' ENTERED AT 16:41:51 ON 03 AUG 2005
L19          3 SEA ABB=ON  PLU=ON  L18 NOT L17
               D STAT QUE
               D IBIB ABS HITSTR L19 1-3


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:    2 AUG 2005  HIGHEST RN 857941-82-3
     DICTIONARY FILE UPDATES:   2 AUG 2005  HIGHEST RN 857941-82-3

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMITS
     for details.

     Experimental and calculated property data are now available. For more
     information enter HELP PROP at an arrow prompt in the file or refer
```

to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

FILE HCAPLUS

FILE COVERS 1907 - 3 Aug 2005 VOL 143 ISS 6
FILE LAST UPDATED: 2 Aug 2005 (20050802/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 16:40:04 ON 03 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Aug 2005 VOL 143 ISS 6
FILE LAST UPDATED: 2 Aug 2005 (20050802/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
=>

=> d stat que l17
L5 STR



Cy 15

VAR G1=CH/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L7 6463 SEA FILE=REGISTRY SSS FUL L5
L15 STR



VAR G1=CH/N
VAR G2=OH/NH
REP G3=(0-20) A
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 17
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L16 42 SEA FILE=REGISTRY SUB=L7 SSS FUL L15
L17 7 SEA FILE=HCAPLUS ABB=ON PLU=ON L16

=>
=>

=> d ibib abs hitstr l17 1-7

L17 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:693093 HCAPLUS Full-text
DOCUMENT NUMBER: 141:359871
TITLE: A series of redox active, tetrathiafulvalene-based amidopyridines and bipyridines ligands: Syntheses, crystal structures, a radical cation salt and group 10 transition-metal complexes

AUTHOR(S): Devic, Thomas; Avarvari, Narcis; Batail, Patrick
CORPORATE SOURCE: Laboratoire Chimie, Ingenierie Moleculaire et Materiaux d'Angers, UMR 6200 CNRS, Universite d'Angers, Angers, 49045, Fr.
SOURCE: Chemistry--A European Journal (2004), 10(15), 3697-3707
CODEN: CEUJED; ISSN: 0947-6539
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Amidopyridine and -2,2'-bipyridine derivs. of EDT-TTF and BTM-TTF (EDT = ethylenedithio, BTM = bis(thiomethyl), TTF = tetrathiafulvalene) were synthesized and crystallog. characterized. In the solid state, the different supramol. organization of all these donors results from the competition between the intermol. interactions, i.e., van der Waals, H-bonding, π-π stacking, and donor-acceptor interactions. The electron-donating properties of the new donors were studied by cyclic voltammetry measurements. A radical cation salt, formulated [EDT-TTF-CONH-m-Py].+[PF6]-, was prepared by electrocrystn. and its crystal structure determined by x-ray anal. Square planar dicationic complexes with the same donor and MIIL2 fragments (M = Pd, Pt, L2 = bis(diphenylphosphino)propane (dppp) or bis(diphenylphosphino)ethane (dppe)) were synthesized and one of them, containing the Pd(dppp) unit, was structurally characterized. The conformation of the complex in the crystalline state is anti, with the coexistence of the DL racemic pair of enantiomers.

IT **774578-84-6P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and crystal structure)
RN 774578-84-6 HCAPLUS
CN 1,3-Dithiole-4-carboxamide, N,N'-pyridinediylbis[2-[4,5-bis(methylthio)-1,3-dithiol-2-ylidene]-, compd. with pyridine (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 774578-74-4
CMF C28 H22 N4 O2 S12



CM 2

CRN 110-86-1
CMF C5 H5 N

IT **774578-74-4P**

RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(preparation and cyclic voltammetry)

RN 774578-74-4 HCAPLUS

CN 1,3-Dithiole-4-carboxamide, N,N'-[2,2'-bipyridine]-5,5'-diylbis[2-[4,5-bis(methylthio)-1,3-dithiol-2-ylidene]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:531358 HCAPLUS Full-text

DOCUMENT NUMBER: 141:89014

TITLE: Preparation of pyridylcyclohexyl phenylpropanamide derivatives as NR2B receptor antagonists

INVENTOR(S): Kawai, Makoto; Nakamura, Hiroshi; Shimokawa, Hirohisa

PATENT ASSIGNEE(S): Pfizer Japan Inc., Japan; Pfizer Inc.

SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054579	A1	20040701	WO 2003-IB5757	20031205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004152715	A1	20040805	US 2003-737309	20031216
PRIORITY APPLN. INFO.:			US 2002-434361P P	20021217

OTHER SOURCE(S): MARPAT 141:89014

GI



I



II

AB Title compds. I [wherein R2 = H or OH; or R forms a covalent bond with ring A; R3 = H or alkyl; R4 = (un)substituted (hetero)aryl; R5 = OH or alkylsulfonylamino; R6 = H, halo, alkylalkoxy; A = cycloalkylene; X = a covalent bond, alkylene, (hetero)alkenylene, etc.; Z = C or N; and pharmaceutically acceptable ester or salts thereof] were prepared as. For example, II•HCl was given in 5-step synthesis starting from trans-4-aminocyclohexanol and 3-phenylpropanoic acid. I showed Ki values from 2.7 μM to 8.9 μM with respect to inhibition of binding at the NR2B receptor. Thus, I and their pharmaceutical compns. are useful for the treatment of disease conditions caused by over activation of NMDA NR2B receptor such as pain, or the like in mammals.

IT **713526-51-3P 713526-55-7P 713526-58-0P**
713526-64-8P 713526-67-1P 713526-72-8P
713526-76-2P 713526-79-5P 713526-80-8P
713526-82-0P 713526-84-2P 713526-89-7P
713526-90-0P 713526-91-1P 713526-93-3P
713526-94-4P 713526-95-5P 713526-96-6P
713526-98-8P 713526-99-9P 713527-01-6P
713527-03-8P 713527-04-9P 713527-05-0P
713527-07-2P 713527-09-4P 713527-13-0P
713527-16-3P 713527-18-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(2-pyridyl)cyclohexyl phenylpropanamides as NMDA NR2B receptor antagonists)

RN 713526-51-3 HCAPLUS

CN Benzenepropanamide, N-[cis-4-hydroxy-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 713526-55-7 HCAPLUS
CN Benzenepropanamide, 4-chloro-N-[cis-4-hydroxy-4-(5-hydroxy-2-pyridinyl)cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-58-0 HCAPLUS
CN Benzenepropanamide, 4-fluoro-N-[cis-4-hydroxy-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-64-8 HCAPLUS
CN Benzenepropanamide, N-[cis-4-hydroxy-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-67-1 HCAPLUS
CN Benzenepropanamide, N-[trans-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 713526-72-8 HCAPLUS
CN Benzenepropanamide, N-[trans-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 713526-76-2 HCAPLUS
CN Benzenepropanamide, 2,4-dichloro-N-[cis-4-hydroxy-4-(5-hydroxy-2-pyridinyl)cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-79-5 HCAPLUS
CN Benzenepropanamide, N-[cis-4-hydroxy-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-4-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-80-8 HCAPLUS
CN Benzenepropanamide, 2-fluoro-N-[cis-4-hydroxy-4-(5-hydroxy-2-pyridinyl)cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-82-0 HCAPLUS
CN Acetamide, N-[cis-4-hydroxy-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-2-(phenylthio)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-84-2 HCAPLUS
CN Benzenepropanamide, 2-fluoro-N-[trans-4-(5-hydroxy-2-pyridinyl)cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-89-7 HCAPLUS
CN Benzenepropanamide, 4-fluoro-N-[trans-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-90-0 HCAPLUS
CN Acetamide, N-[trans-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-2-(phenylthio)-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-91-1 HCAPLUS
CN Benzenepropanamide, 4-ethyl-N-[trans-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-93-3 HCAPLUS
CN Benzenepropanamide, 2-chloro-N-[trans-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-94-4 HCAPLUS
CN Benzenepropanamide, 2,4-dichloro-N-[trans-4-(5-hydroxy-2-pyridinyl)cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-95-5 HCAPLUS
CN Benzenepropanamide, 4-chloro-N-[trans-4-(5-hydroxy-2-pyridinyl)cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-96-6 HCAPLUS
CN Benzenepropanamide, N-[trans-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-4-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-98-8 HCAPLUS
CN Benzenepropanamide, N-[trans-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-2-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-99-9 HCAPLUS
CN Acetamide, N-[cis-4-hydroxy-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-N-methyl-2-(phenylthio)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713527-01-6 HCAPLUS
CN Benzenepropanamide, 2-fluoro-N-[cis-4-hydroxy-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713527-03-8 HCAPLUS
CN Benzenepropanamide, 4-chloro-N-[cis-4-hydroxy-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713527-04-9 HCAPLUS
CN Benzenepropanamide, N-[cis-4-hydroxy-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-N,4-dimethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713527-05-0 HCAPLUS
CN Carbamic acid, [trans-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713527-07-2 HCAPLUS
CN Benzenepropanamide, N-[4-(5-hydroxy-2-pyridinyl)-3-cyclohexen-1-yl]- (9CI) (CA INDEX NAME)



RN 713527-09-4 HCAPLUS
CN Urea, N'-[(2-fluorophenyl)methyl]-N-[cis-4-hydroxy-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713527-13-0 HCAPLUS
CN Benzenepropanamide, 2-fluoro-N-[1-(5-hydroxy-2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 713527-16-3 HCAPLUS
CN Benzenepropanamide, N-[1-(5-hydroxy-2-pyridinyl)-4-piperidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 713527-18-5 HCAPLUS
CN 2-Propenamide, N-[trans-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-3-phenyl-, (2E)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT **713527-08-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-(2-pyridyl)cyclohexyl phenylpropanamides as NMDA NR2B receptor antagonists)
RN 713527-08-3 HCAPLUS
CN Benzenepropanamide, N-[4-hydroxy-4-(5-hydroxy-2-pyridinyl)cyclohexyl]- (9CI) (CA INDEX NAME)



IT **713526-54-6P 713526-63-7P 713526-71-7P 713526-75-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(2-pyridyl)cyclohexyl phenylpropanamides as NMDA NR2B receptor antagonists)
RN 713526-54-6 HCAPLUS
CN Benzenepropanamide, N-[cis-4-hydroxy-4-(5-hydroxy-2-pyridinyl)cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-63-7 HCAPLUS
CN Benzenepropanamide, 4-fluoro-N-[cis-4-hydroxy-4-(5-hydroxy-2-pyridinyl)cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-71-7 HCAPLUS
CN Benzenepropanamide, N-[trans-4-(5-hydroxy-2-pyridinyl)cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 713526-75-1 HCAPLUS
CN Benzenepropanamide, N-[trans-4-(5-hydroxy-2-pyridinyl)cyclohexyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:473270 HCAPLUS Full-text
DOCUMENT NUMBER: 139:36444
TITLE: Preparation of substituted ureas as neuropeptide Y5 receptor antagonists
INVENTOR(S): Greenlee, William J.; Huang, Ying; Kelly, Joseph M.; McCombie, Stuart W.; Stamford, Andrew W.; Wu, Yusheng
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 108 pp., Cont.-in-part of U.S. Ser. No. 950,908.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2003114517	A1	20030619	US 2002-96390		20020312
US 6894063	B2	20050517			
US 2002165223	A1	20021107	US 2001-950908		20010912
US 2005038100	A1	20050217	US 2004-933016		20040901
PRIORITY APPLN. INFO.:			US 2000-232255P	P	20000914
			US 2001-950908	A2	20010912
			US 2002-96390	A3	20020312

OTHER SOURCE(S): MARPAT 139:36444
GI


I


II


III


IV


V


VI

AB The title compds. [I; Y = II, III; R1 = H, alkyl; R2 = H, alkyl, cycloalkyl, etc.; R3 = IV, V, etc.; j = 0-2; k = 1-2; l = 0-2; m = 0-2; p = 1-3; r = 1-3; R4 = H, OH, halo, etc.; R5 = H, halo, OH, etc.; R6 = alkylSO2, cycloalkylSO2, heteroarylalkyl, etc.;], useful as neuropeptide Y5 receptor antagonists for treating obesity, hyperphagia, type II diabetes, insulin resistance, and hypertension, were prepared E.g., a multi-step synthesis of VI, was given. For the compds. I, a range of neuropeptide Y5 receptor binding activity from about 0.2 nM to about 500 nM was observed Methods of preparing pharmaceutical formulations comprising one or more such compds. I were claimed.

IT **405056-07-7P 405056-14-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted ureas as neuropeptide Y5 receptor antagonists)

RN 405056-07-7 HCAPLUS
CN Urea, N'-(3',5'-difluoro[1,1'-biphenyl]-4-yl)-N-[1-(5-hydroxy-2-pyridinyl)-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 405056-14-6 HCAPLUS
CN Urea, N-[1-(5-amino-2-pyrimidinyl)-4-piperidinyl]-N'-(3',5'-difluoro[1,1'-biphenyl]-4-yl)-N-methyl- (9CI) (CA INDEX NAME)



L17 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:220568 HCAPLUS Full-text
DOCUMENT NUMBER: 136:263169
TITLE: Preparation of Substituted ureas as neuropeptide Y5 receptor antagonists
INVENTOR(S): Greenlee, William J.; Huang, Ying; Kelly, Joseph M.; McCombie, Stuart W.; Stamford, Andrew W.; Wu, Yusheng
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022592	A2	20020321	WO 2001-US28324	20010912
WO 2002022592	A3	20020627		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422013	AA	20020321	CA 2001-2422013	20010912
AU 2001094547	A5	20020326	AU 2001-94547	20010912
EP 1322628	A2	20030702	EP 2001-975194	20010912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509108	T2	20040325	JP 2002-526845	20010912
PRIORITY APPLN. INFO.:			US 2000-232255P P	20000914
			WO 2001-US28324 W	20010912

OTHER SOURCE(S): MARPAT 136:263169
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; A = Q, Q1; R1 = H, F, Cl, CF3, OH; R2 = H, F, Cl, CF3, CN, OCH3, OH; R3 = H, F, Cl, CF3, OCF3, CN, OCH2C6H5, OH; R4 = H, F, Cl; X = NH, NCH3; n = 0, 1, 2; Y = NR5, C:NOH; R5 = SO2CH3, SO2(CH2)2CH3, cyclopropylmethyl, 3-pyridyl, 2-pyridyl, 2-thiazolyl, 2-pyrimidyl, 1-oxo-3-pyridyl, SO2NH2, CH2CONH2, CONH2, NHSO2CH3, SO2(CH2)2OH, C(:NCN)NHCH3, C(:NCN)SCH3, 3-pyridylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, CON(CH3)2, cyclohexyl; R6 = H, F, Br, Cl, OCH3, OH; R7 = H, F, Cl, OCH3; etc.], stereoisomers, N-oxides, pharmaceutically acceptable salts or hydrates, and prodrugs are disclosed as neuropeptide Y5 receptor antagonists. Method of treating obesity, hyperphagia, type II diabetes, insulin resistance, and hypertension involving title compds. I are claimed. Thus, the title compound II was prepared from N-tert-butoxycarbonyl-4-piperidone, 4-bromophenyl isocyanate, 2-fluorophenylboronic acid, and methanesulfonyl chloride in multiple steps.

IT **405056-07-7P 405056-14-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted ureas as neuropeptide Y5 receptor antagonists)

RN 405056-07-7 HCAPLUS
CN Urea, N'-(3',5'-difluoro[1,1'-biphenyl]-4-yl)-N-[1-(5-hydroxy-2-pyridinyl)-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 405056-14-6 HCAPLUS
CN Urea, N-[1-(5-amino-2-pyrimidinyl)-4-piperidinyl]-N'-(3',5'-difluoro[1,1'-biphenyl]-4-yl)-N-methyl- (9CI) (CA INDEX NAME)



L17 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:321038 HCAPLUS Full-text
DOCUMENT NUMBER: 131:53145
TITLE: Design, syntheses, complexation, and electrochemistry of polynuclear metallodendrimers possessing internal metal binding loci
AUTHOR(S): Newkome, George R.; Patri, Anil K.; Godinez, Luis A.
CORPORATE SOURCE: Center for Molecular Design and Recognition, Department of Chemistry, University of South Florida, Tampa, FL, 33620, USA

SOURCE: Chemistry--A European Journal (1999), 5(5), 1445-1451
CODEN: CEUJED; ISSN: 0947-6539
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Extended, branched monomers possessing bipyridine moieties were synthesized using high dilution conditions, then used in the assembly of macromol. constructs. Dendrimers with four internal bipyridine (bpy') units at precise locations within the superstructure were transformed into their [Ru(bpy')(bpy)2]2+ (bpy = 2,2'-bipyridine) complexes. The absorption spectra and cyclic voltammetry measurements of these polynuclear dendritic bipyridine Ru(II) complexes were measured and used to confirm their composition

IT **227175-93-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(for preparation of bipyridine-containing dendrimer ligand)

RN 227175-93-1 HCAPLUS

CN Heptanedioic acid, 4,4'-[[2,2-bis[[3-[[5'-[[5-[[3-carboxy-1,1-bis(2-carboxyethyl)propyl]amino]-1,5-dioxopentyl]amino][2,2'-bipyridin]-5-yl]amino]-3-oxopropoxy]methyl]-1,3-propanediyl]bis[oxy(1-oxo-3,1-propanediyl)imino[2,2'-bipyridine]-5',5-diylimino(1,5-dioxo-5,1-pentanediyl)imino]]bis[4-(2-carboxyethyl)- (9CI) (CA INDEX NAME)

PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-A



PAGE 3-B



IT **227175-92-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, deprotection, and complexation with ruthenium bis(bipyridine) dichloro complex)
RN 227175-92-0 HCAPLUS
CN Heptanedioic acid, 4,4'-[[2,2-bis[[3-[[5'-[[5-[[4-(1,1-dimethylethoxy)-1,1-bis[3-(1,1-dimethylethoxy)-3-oxopropyl]-4-oxobutyl]amino]-1,5-dioxopentyl]amino][2,2'-bipyridin]-5-yl]amino]-3-oxopropoxy]methyl]-1,3-propanediyl]bis[oxy(1-oxo-3,1-propanediyl)imino[2,2'-bipyridine]-5',5-diylimino(1,5-dioxo-5,1-pentanediyl)imino]]bis[4-[3-(1,1-dimethylethoxy)-3-oxopropyl]-, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-A





REFERENCE COUNT: 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1989:90608 HCAPLUS Full-text
DOCUMENT NUMBER: 110:90608
TITLE: Fruit thinning agents containing pyrazoles
INVENTOR(S): Kato, Shozo; Noma, Yutaka; Igami, Satoyoshi
PATENT ASSIGNEE(S): Tokuyama Soda Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 27 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63174905	A2	19880719	JP 1987-4945	19870114
JP 07106964	B4	19951115		
PRIORITY APPLN. INFO.:			JP 1987-4945	19870114

OTHER SOURCE(S): MARPAT 110:90608
GI For diagram(s), see printed CA Issue.
AB Fruit thinning agents containing title compds. I [R = H, alkyl, (substituted) Ph; R1-R5 = H, halo, (substituted) alkyl, alkoxy, alkylthio, alkoxyalkyl, OH, NO2, cyano; R1R2 forms ring; R6 = H, (substituted) alkyl, (substituted) Ph, (substituted) pyridyl; A = CH,N; n ≥ 0] as active ingredients are described. A solution of 5-amino-1,3-dimethylpyrazole in C6H6 was treated with 2,4-MeClC6H3OCHMeCOCl to give 84.8% N-pyrazolylpropanamide derivative II, which at 200 ppm showed fruit thinning to 23.8% in mandarin orange. A wettable powder was formulated containing II 10, polyoxyethylene nonylphenyl ether 2, clay 40, and zeolite 48 weight parts.
IT **118912-52-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as fruit thinning agent)
RN 118912-52-0 HCAPLUS
CN Propanamide, 3-(2,4-dichlorophenoxy)-N-[1-(5-hydroxy-2-pyridinyl)-3,5-dimethyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L17 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1987:576028 HCAPLUS Full-text
DOCUMENT NUMBER: 107:176028
TITLE: Preparation of [(phenoxyalkanoyl)amino]pyrazole derivatives as herbicides, fungicides and bactericides
INVENTOR(S): Kato, Shozo; Takematsu, Tetsuo; Igami, Satoyoshi; Ogasawara, Masaru
PATENT ASSIGNEE(S): Tokuyama Soda Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62138475	A2	19870622	JP 1985-277887	19851212
JP 05080469	B4	19931109		
PRIORITY APPLN. INFO.:			JP 1985-277887	19851212

GI



I



II

AB The title compds. I [R1-R5 = H, halo, (un)substituted alkyl, alkoxy(alkyl), alkylthio, OH, NO2, cyano, or R1R2 being adjacent and completing a fused ring; R6 = (un)substituted alkyl, Ph or pyridyl; n = integer], useful as herbicides, fungicides and bactericides, were prepared A solution of 0.0042 mmol 2,4-Cl2C6H3OCH2COCl in benzene was added dropwise to a solution of 0.0032 mmol 5-amino-1,3-dimethylpyrazole and 0.0042 mmol Et3N in benzene and the mixture was stirred overnight to give 0.85 g a pyrazole derivative II (R7 = H, R8 = Me). In preemergence period, I at 100g/10 are controlled by 90-100% various weeds, e.g., Scirpus juncoides. II (R7 = Cl, R8 = 3,4-dichlorophenyl) in vitro is active against fungi, e.g., Pellicularia sasaki and a bacterium, Staphylococcus aureus.

IT **110731-75-4P**

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide, fungicide and bactericide)

RN 110731-75-4 HCAPLUS

CN Acetamide, 2-(2,4-dichlorophenoxy)-N-[1-(5-hydroxy-2-pyridinyl)-3,5-dimethyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





=> _

=> d stat que
L5 STR



Cy 15

VAR G1=CH/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L7 6463 SEA FILE=REGISTRY SSS FUL L5
L12 STR



VAR G1=CH/N
VAR G2=OH/NH
REP G3=(0-20) A
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 17
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L13 84 SEA FILE=REGISTRY SUB=L7 SSS FUL L12

L15 STR



VAR G1=CH/N
VAR G2=OH/NH
REP G3=(0-20) A
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 17
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L16 42 SEA FILE=REGISTRY SUB=L7 SSS FUL L15
L17 7 SEA FILE=HCAPLUS ABB=ON PLU=ON L16
L18 42 SEA FILE=REGISTRY ABB=ON PLU=ON L13 NOT L16
L19 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 NOT L17

=>
=>

=> d ibib abs hitstr l19 1-3

L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:334911 HCAPLUS Full-text
DOCUMENT NUMBER: 138:354000
TITLE: Preparation of dihydroxypyrimidine carboxamide inhibitors of HIV integrase
INVENTOR(S): Di Francesco, Maria Emilia; Gardelli, Cristina; Harper, Steven; Matassa, Victor Giulio; Muraglia, Ester; Nizi, Emanuela; Pace, Paola; Pacini, Barbara; Petrocchi, Alessia; Poma, Marco; Summa, Vincenzo
PATENT ASSIGNEE(S): Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa, Italy
SOURCE: PCT Int. Appl., 315 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035076	A1	20030501	WO 2002-GB4742	20021021

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2463975	AA	20030501	CA 2002-2463975		20021021
EP 1441734	A1	20040804	EP 2002-801949		20021021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
JP 2005510500	T2	20050421	JP 2003-537643		20021021
US 2005075356	A1	20050407	US 2004-493279		20040420
PRIORITY APPLN. INFO.:			US 2001-348195P	P	20011026
			WO 2002-GB4742	W	20021021

OTHER SOURCE(S): MARPAT 138:354000

GI



I

AB The title 4,5-dihydroxypyrimidine-6-carboxamides [I; R1 = H, alkyl, haloalkyl, alkoxy, etc.; R2 = H, alkyl, haloalkyl, hydroxyalkyl, etc.; R3 = H, alkyl; R4 = H, alkyl, haloalkyl, etc.] which are inhibitors of HIV integrase and inhibitors of HIV replication, and therefore are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS, were prepared Thus, refluxing N-hydroxythiophene-2-carboximidamide with di-Me acetylenedicarboxylate in CHCl3 followed by reacting the resulting Me 5,6-dihydroxy-2-(2- thienyl)pyrimidine-4-carboxylate with 4-fluorobenzylamine in DMF afforded I [R1 = 2-thienyl; R2 = H; R3 = 4-FC6H4CH2; R4 = H]. The compds. I are employed against HIV infection and AIDS as compds. per se or in the form of pharmaceutically acceptable salts. The compds. I and their salts can be employed as ingredients in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

IT **519021-82-0P 519022-03-8P 519022-78-7P**
519022-79-8P 519023-05-3P 519023-07-5P
519023-09-7P 519023-10-0P 519023-12-2P
519023-13-3P 519023-14-4P 519023-15-5P
519023-16-6P 519023-17-7P 519023-18-8P
519023-65-5P 519023-69-9P 519023-70-2P
519023-73-5P 519023-75-7P 519023-77-9P
519023-78-0P 519024-20-5P 519028-23-0P
519028-24-1P 519032-30-5P 519032-31-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydroxypyrimidine carboxamide inhibitors of HIV integrase)

RN 519021-82-0 HCAPLUS
CN Carbamic acid, [2-[1,4-dihydro-5-hydroxy-4-oxo-6-[[(phenylmethyl)amino]carbonyl]-2-pyrimidinyl]-3-thienyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 519022-03-8 HCAPLUS
CN 4-Pyrimidinecarboxamide, 2-[3-[[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 519022-78-7 HCAPLUS
CN 4-Pyrimidinecarboxamide, 2-[3-[[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 519022-79-8 HCAPLUS
CN 4-Pyrimidinecarboxamide, N-[(2-chlorophenyl)methyl]-2-[3-[[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 519023-05-3 HCAPLUS
CN Carbamic acid, [2-[[2-[6-(aminocarbonyl)-1,4-dihydro-5-hydroxy-4-oxo-2-pyrimidinyl]-3-thienyl]amino]-2-oxo-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 519023-07-5 HCAPLUS
CN 4-Pyrimidinecarboxamide, 2-[3-[(aminophenylacetyl)amino]-2-thienyl]-1,6-dihydro-5-hydroxy-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519023-06-4
CMF C17 H15 N5 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 519023-09-7 HCAPLUS
CN 4-Pyrimidinecarboxamide, 2-[3-[(aminophenylacetyl)amino]-2-thienyl]-1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519023-08-6
CMF C24 H21 N5 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 519023-10-0 HCAPLUS
CN 4-Pyrimidinecarboxamide, N-[(3-chlorophenyl)methyl]-2-[4-[[[[(2-chlorophenyl)sulfonyl]amino]carbonyl]amino]-3-thienyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 519023-12-2 HCAPLUS
CN 4-Pyrimidinecarboxamide, 2-[4-[[[[(2,3-dichlorophenyl)methyl]amino]carbonyl]amino]-3-thienyl]-1,6-dihydro-5-hydroxy-N-methyl-6-oxo- (9CI) (CA INDEX NAME)



RN 519023-13-3 HCAPLUS
CN 4-Pyrimidinecarboxamide, 2-[4-[[[[(2-chlorophenyl)sulfonyl]amino]carbonyl]amino]-3-thienyl]-N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 519023-14-4 HCAPLUS
CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)-2-[4-

[[[(phenylmethyl)amino]carbonyl]amino]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 519023-15-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-[[[[(2-chlorophenyl)sulfonyl]amino]carbonyl]amino]-3-thienyl]-1,6-dihydro-5-hydroxy-6-oxo-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 519023-16-6 HCAPLUS

CN 4-Pyrimidinecarboxamide, 2-[4-[[[[(2-chlorophenyl)sulfonyl]amino]carbonyl]amino]-3-thienyl]-1,6-dihydro-5-hydroxy-N-methyl-6-oxo- (9CI) (CA INDEX NAME)



RN 519023-17-7 HCAPLUS

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)-2-[4-[[[(2-thienylmethyl)amino]carbonyl]amino]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 519023-18-8 HCAPLUS

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-N-methyl-6-oxo-2-[4-[[[(phenylsulfonyl)amino]carbonyl]amino]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 519023-65-5 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[2-[(2-pyridinylcarbonyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 519023-69-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[2-[(4-pyridinylcarbonyl)amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 519023-70-2 HCAPLUS
CN 4-Pyrimidinecarboxamide, 2-[2-[[[[(2,3-dichlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 519023-73-5 HCAPLUS
CN 4-Pyrimidinecarboxamide, 2-[2-[[[[(2,5-dichlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 519023-75-7 HCAPLUS
CN 4-Pyrimidinecarboxamide, N-[(2,3-dimethoxyphenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[2-[(3-pyridinylcarbonyl)amino]phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519023-74-6
CMF C26 H23 N5 O6



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 519023-77-9 HCAPLUS
CN 4-Pyrimidinecarboxamide, 2-[2-[(2-amino-1-oxo-3-phenylpropyl)amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519023-76-8
CMF C20 H19 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 519023-78-0 HCAPLUS
CN Carbamic acid, [2-[[2-[6-(aminocarbonyl)-1,4-dihydro-5-hydroxy-4-oxo-2-pyrimidinyl]phenyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 519024-20-5 HCAPLUS
CN 4-Pyrimidinecarboxamide, 2-[3-[[[[(3,4-dichlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 519028-23-0 HCAPLUS
CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[1-[(2-pyridinylcarbonyl)amino]cyclohexyl]- (9CI) (CA INDEX NAME)



RN 519028-24-1 HCAPLUS
CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[1-[(2-pyridinylcarbonyl)amino]cyclohexyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519028-23-0

CMF C24 H24 F N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 519032-30-5 HCAPLUS
CN 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-6-oxo-2-[1-[(pyrazinylcarbonyl)amino]cyclopropyl]- (9CI) (CA INDEX NAME)



RN 519032-31-6 HCAPLUS
CN Carbamic acid, [1-[6-[[[(4-fluorophenyl)methyl]amino]carbonyl]-1,4-dihydro-5-hydroxy-4-oxo-2-pyrimidinyl]cyclopentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



IT **519032-05-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydroxypyrimidine carboxamide inhibitors of HIV integrase)
RN 519032-05-4 HCAPLUS
CN 4-Pyrimidinecarboxylic acid, 2-[4-[[[[(2-chlorophenyl)sulfonyl]amino]carbonyl]amino]-3-thienyl]-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:72061 HCAPLUS Full-text
DOCUMENT NUMBER: 136:118465
TITLE: Preparation of 2-aryldihydroxypyrimidine-4-carboxylic acids as hepatitis C viral polymerase inhibitors
INVENTOR(S): Gardelli, Cristina; Giuliano, Claudio; Harper, Steven; Koch, Uwe; Narjes, Frank; Ontoria Ontoria, Jesus Maria; Poma, Marco; Ponzi, Simona; Stansfield, Ian; Summa, Vincenzo
PATENT ASSIGNEE(S): Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A., Italy
SOURCE: PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006246	A1	20020124	WO 2001-EP7955	20010711

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2418288	AA	20020124	CA 2001-2418288		20010711
EP 1309566	A1	20030514	EP 2001-951664		20010711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004504304	T2	20040212	JP 2002-512150		20010711
US 2004106627	A1	20040603	US 2003-333431		20030709
PRIORITY APPLN. INFO.:			GB 2000-17676	A	20000719
			WO 2001-EP7955	W	20010711

OTHER SOURCE(S): MARPAT 136:118465

AB RR1 (R1 = 4-carboxy-5,6-dihydroxy-2-pyrimidinyl)[I; R = (un)substituted (hetero)aryl] were prepared Thus, 2-(O2N)C6H4C(:NOH)NH2 (preparation given) N-was alkenylated by MeO2CC.tplbond.CCO2Me and the product cyclized to give, after reduction, N-acylation, and saponification, I [R = 2-(2-ClC6H4CH2NHCONH)C6H4]. Data for biol. activity of I were given.

IT **391680-76-5P 391680-77-6P 391680-80-1P 391680-81-2P 391680-82-3P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-aryldihydroxypyrimidine-4-carboxylic acids as hepatitis C viral polymerase inhibitors)

RN 391680-76-5 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 391680-77-6 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(diphenylmethyl)amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 391680-80-1 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 391680-81-2 HCAPLUS
CN 4-Pyrimidinecarboxylic acid, 2-[4-[[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]-3-thienyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 391680-82-3 HCAPLUS
CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[4-[[[(1-naphthalenylsulfonyl)amino]carbonyl]amino]-3-thienyl]-6-oxo- (9CI) (CA INDEX NAME)



IT **391680-87-8P 391681-04-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-aryldihydroxypyrimidine-4-carboxylic acids as hepatitis C viral polymerase inhibitors)

RN 391680-87-8 HCAPLUS
CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 391681-04-2 HCAPLUS
CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[4-[[[(1-naphthalenylsulfonyl)amino]carbonyl]amino]-3-thienyl]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:858552 HCAPLUS Full-text
DOCUMENT NUMBER: 136:247463
TITLE: Synthesis and pharmacological evaluation of (indol-3-yl)alkylamides as potent analgesic agents
AUTHOR(S): Fouchard, Fabienne; Marchand, Pascal; Le Baut, Guillaume; Emig, Peter; Nickel, Bernd
CORPORATE SOURCE: Laboratoires de Chimie Organique et de Chimie Therapeutique, Faculte de Pharmacie, Nantes, 44035, Fr.
SOURCE: Arzneimittel-Forschung (2001), 51(10), 814-824
CODEN: ARZNAD; ISSN: 0004-4172
PUBLISHER: Editio Cantor Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:247463
AB A series of (indol-3-yl)alkylamides was synthesized and evaluated for analgesic activity. Two N-(pyridin-4-yl)acetamides, bearing benzyl or 4-

fluorobenzyl moieties in 1-position of indole ring, exhibited promising analgesic properties (ED50 = 8.1 and 11 mg/kg p.o., resp.). The two test compds. were tested for their anti-inflammatory activity by carrageenin-induced edema in rat paw test. 4-Fluorobenzyl derivative whose ID50 was 0.085 ± 0.021 mmol/kg was selected as a lead compound for further pharmacomodulation.

IT **404018-29-7P 404018-30-0P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and analgesic and anti-inflammatory activities of (indol-3-yl)alkylamides)

RN 404018-29-7 HCAPLUS

CN Carbamic acid, [2-amino-6-[4-[(1H-indol-3-ylacetyl)amino]-1-piperidinyl]-3-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 404018-30-0 HCAPLUS

CN Carbamic acid, [2-amino-6-[4-[[3-(1H-indol-3-yl)-1-oxopropyl]amino]-1-piperidinyl]-3-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>